Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis

BACKGROUND: Eculizumab is a humanized monoclonal antibody that targets complement protein C5 and inhibits terminal complement-mediated damage at the neuromuscular junction. Recently, the REGAIN study showed that eculizumab was effective and well tolerated in patients with anti-acetylcholine receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Oyama, Munenori, Okada, Kensuke, Masuda, Masayuki, Shimizu, Yuko, Yokoyama, Kazumasa, Uzawa, Akiyuki, Kawaguchi, Naoki, Ikeguchi, Ryotaro, Hoshino, Yasunobu, Hatano, Taku, Ozawa, Yukiko, Nakahara, Jin, Aizawa, Hitoshi, Kitagawa, Kazuo, Hattori, Nobutaka, Kuwabara, Satoshi, Murai, Hiroyuki, Suzuki, Shigeaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Autoimmune Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081459/
https://www.ncbi.nlm.nih.gov/pubmed/32215054
http://dx.doi.org/10.1177/1756286420904207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081459/
https://www.ncbi.nlm.nih.gov/pubmed/32215054
http://dx.doi.org/10.1177/1756286420904207

Ejemplares similares